Understanding how certain cells contribute to lung scarring
Official title: Novel Mechanisms of Pulmonary Fibrosis
Funded at University of Cincinnati · NIH-11088228 · Data updated 2026-11-12
This study is looking at how certain cells in the lungs might contribute to lung scarring in conditions like silicosis, and it’s inviting patients to help by sharing lung tissue samples or joining in related check-ups to help find better treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Cincinnati NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project start | May 20, 2023 |
| Project end | April 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $613,518 |
| NIH project number | 5R01HL162261-03 |
| Project ID | NIH-11088228 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation include individuals diagnosed with silicosis or other forms of pulmonary fibrosis.
✕Less likely to help
Patients with pulmonary conditions unrelated to fibrosis or those without a history of exposure to silica may not benefit from this research.
What this research studies
This research investigates the role of a specific type of cell, known as pulmonary osteoclast-like cells (POLCs), in the development of pulmonary fibrosis, particularly in conditions like silicosis. The study utilizes advanced techniques such as single-cell RNA sequencing to analyze lung tissue and identify how these cells interact with other immune cells in the lungs. By examining the molecular mechanisms involved, the research aims to uncover potential pathways that lead to lung damage and fibrosis, which could inform future treatments. Patients may be able to contribute to this research by providing lung tissue samples or participating in related clinical assessments.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for preventing or treating pulmonary fibrosis.
How similar studies have gone: Previous research has shown promising results in understanding the role of immune cells in lung diseases, suggesting that this approach could yield valuable insights.
Where this research is happening
-
University of Cincinnati
Cincinnati, United States Active
Researchers
- Principal investigator: Mccormack, Francis Xavier — University of Cincinnati
- Study coordinator: Mccormack, Francis Xavier
Related research
Other NIH-funded projects on the same topics.
-
Molecular clues to progressive lung scarring
Researchers are studying how lung tissue becomes progressively scarred, focusing on cell signals and receptors that may drive fibrosis in people with lung disease.
-
Alveolar Cell Dysfunction in Pulmonary Fibrosis: Using SFTPC Mutations to Find New Targets
This grant explores how rare SFTPC mutations in alveolar cells may drive IPF and seeks new molecular targets to improve treatment.
-
Iron and scar-forming cells in the lungs (IPF)
Researchers are exploring how iron in the lungs may drive the scarring seen in idiopathic pulmonary fibrosis and whether this could lead to new therapies.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
Role of lactate transporters in lung scarring
Aims to see if blocking lactate transporters can slow or stop scar-forming cells from thickening the lungs in people with fibrotic lung disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.